Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$18.67 - $24.56 $2.55 Million - $3.35 Million
-136,368 Reduced 56.1%
106,711 $2.6 Million
Q4 2022

Feb 14, 2023

BUY
$17.24 - $23.95 $904,789 - $1.26 Million
52,482 Added 27.54%
243,079 $5.2 Million
Q3 2022

Nov 14, 2022

BUY
$9.4 - $18.59 $1.79 Million - $3.54 Million
190,597 New
190,597 $3.42 Million
Q2 2022

Aug 15, 2022

SELL
$9.12 - $18.9 $4.6 Million - $9.53 Million
-504,371 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$12.15 - $16.83 $6.13 Million - $8.49 Million
504,371 New
504,371 $8.49 Million
Q4 2021

Feb 14, 2022

SELL
$13.83 - $18.78 $5.22 Million - $7.09 Million
-377,708 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$7.07 - $17.5 $1.99 Million - $4.92 Million
280,888 Added 290.11%
377,708 $6.13 Million
Q2 2021

Aug 16, 2021

BUY
$5.69 - $7.17 $550,905 - $694,199
96,820 New
96,820 $611,000

Others Institutions Holding ISEE

About IVERIC bio, Inc.


  • Ticker ISEE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 118,078,000
  • Description
  • IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...
More about ISEE
Track This Portfolio

Track Tri Locum Partners LP Portfolio

Follow Tri Locum Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tri Locum Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Tri Locum Partners LP with notifications on news.